Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8781421 | 1.00 | HTT (0.65) | HTTALDH1A1SMN1; SMN2HPGDNPC1 | |
| SCHEMBL6190463 | 0.85 | HTT (0.63) | HTTALDH1A1SMN1; SMN2HPGDNPC1 | |
| SCHEMBL15134835 | 0.85 | HTT (0.72) | HTTALDH1A1SMN1; SMN2HPGDNPC1 | |
| SCHEMBL10373273 | 0.84 | HTT (0.62) | HTTALDH1A1SMN1; SMN2HPGDNPC1 | |
| SCHEMBL6794958 | 0.82 | MAPT (0.58) | HTTALDH1A1SMN1; SMN2HPGDNPC1 | |
| SCHEMBL7232816 | 0.82 | MAPT (0.58) | HTTALDH1A1SMN1; SMN2HPGDNPC1 | |
| SCHEMBL7241560 | 0.81 | ALDH1A1 (0.56) | HTTALDH1A1SMN1; SMN2HPGDNPC1 | |
| SCHEMBL7232704 | 0.81 | MAPT (0.54) | HTTALDH1A1SMN1; SMN2HPGDRAB9A | |
| Ammonia Solution, Strong SCHEMBL7239598 | 0.81 | MAPT (0.57) | HTTALDH1A1SMN1; SMN2HPGDNPC1 | |
| SCHEMBL7233063 | 0.81 | MAPT (0.54) | HTTALDH1A1SMN1; SMN2HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113061121-B | Method for catalyzing hydrodesulfurization of thioamide derivative | 精华制药集团南通有限公司 | 2023-04-11 | — | — | CN | disclosed |
| CN-113061121-A | Method for catalyzing hydrodesulfurization of thioamide derivative | 精华制药集团南通有限公司 | 2021-07-02 | — | — | CN | disclosed |
| EP-2343069-A1 | Heterocyclic aspartyl protease inhibitors | Schering Corporation (US) | 2011-07-13 | — | — | EP | disclosed |
| EP-1885725-B1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | HOFFMANN LA ROCHE (CH) | 2008-09-24 | — | — | EP | disclosed |
| EP-1885725-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006108488-A1 | TRICYCLIC AZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| US-20060235013-A1 | Tricyclic azole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | US | disclosed |
| EP-0252474-B1 | HYDRAZINE DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1993-04-21 | — | — | EP | disclosed |
| EP-0525832-A1 | Substituted 1,2,3- thiadiazole-4-thiolates | AMERICAN CYANAMID COMPANY (US) | 1993-02-03 | — | — | EP | disclosed |
| US-4916237-A | Substituted 1,2,3-thiadiazole-4-thiolates | AMERICAN CYANAMID COMPANY (US) | 1990-04-10 | — | — | US | disclosed |
| US-4803280-A | Substituted 1,2,3-thia-diazole-4-thiolates | AMERICAN CYANAMID COMPANY (US) | 1989-02-07 | — | — | US | disclosed |
| EP-0252474-A2 | Hydrazine derivatives | AMERICAN CYANAMID COMPANY (US) | 1988-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060235013-A1 | Tricyclic azole derivatives | CYP3A5, CYP3A43, CYP11B1 | HTT 2838/4885ALDH1A1 204/4885SMN1; SMN2 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.